NEW YORK (
-- Nektar Therapeutics
) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and generally weak debt management.
Nektar Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Nektar has a market cap of $1.1 billion and is part of the
industry. Shares are down 25% year to date as of the close of trading on Thursday.
You can view the full
or get investment ideas from our